Association of pembrolizumab with tumor response and survival among patients with advanced melanoma

- Ribas, Antoni, Hamid, Omid, Gangadhar, Tara C., Hersey, Peter, Dronca, Roxana, Joseph, Richard W., Zarour, Hassane, Chmielowski, Bartosz, Lawrence, Donald P., Algazi, Alain, Rizvi, Naiyer A., Hoffner, Brianna, Daud, Adil, Mateus, Christine, Gergich, Kevin, Lindia, Jill A., Giannotti, Maxine, Li, Xiaoyun Nicole, Ebbinghaus, Scott, Kang, S. Peter, Robert, Caroline, Hodi, F. Stephen, Wolchok, Jedd D., Kefford, Richard, Joshua, Anthony M., Patnaik, Amita, Hwu, Wen-Jen, Weber, Jeffrey S.

Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma

- Daud, Adil I, Wolchok, Jedd D., Joseph, Richard, Gangadhar, Tara C., Dronca, Roxana, Patnaik, Amita, Zarour, Hassane, Roach, Charlotte, Toland, Grant, Lunceford, Jared K., Li, Xiaoyun Nicole, Emancipator, Kenneth, Robert, Caroline, Dolled-Filhart, Marisa, Kang, S. Peter, Ebbinghaus, Scot, Hamid, Omid, Hwu, Wen-Jen, Weber, Jeffrey S., Ribas, Antoni, Hodi, F. Stephen, Joshua, Anthony M., Kefford, Richard, Hersey, Peter

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma

- Hamid, Omid, Robert, Caroline, Dronca, Roxana, Gangadhar, Tara C., Patnaik, Amita, Zarour, Hassane, Joshua, Anthony M., Gergich, Kevin, Elassaiss-Schaap, Jeroen, Algazi, Alain, Mateus, Christine, Boasberg, Peter, Daud, Adil, Tumeh, Paul C., Chmielowski, Bartosz, Ebbinghaus, Scot W., Li, Xiaoyun Nicole, Kang, S. Peter, Ribas, Antoni, Hodi, F. Stephen, Hwu, Wen-Jen, Kefford, Richard, Wolchok, Jedd D., Hersey, Peter, Joseph, Richard W., Weber, Jeffrey S.